Education
About Us
Working with TipRanks
Follow Us
Dynavax Technologies (DVAX)
:DVAX
Earnings Data
Report Date
Feb 19, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.05Last Year’s EPS
0.05Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Q3 2025
Earnings Call Date:Oct 24, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and strategic advancements in the company's pipeline and partnerships, notably with Vaxart. Despite a few concerns about potential seasonal impacts and a decrease in cash reserves, the company's overall financial health and strategic initiatives suggest a positive outlook.Company Guidance
HEPLISAV-B Revenue Growth
HEPLISAV-B generated approximately $90 million in net product revenue this quarter, representing a 13% increase year-over-year. The U.S. adult hepatitis B vaccine market share reached 46%, up from 44% in the prior year period.
Shingles Vaccine Program Progress
Progress was made in the shingles vaccine program with the initiation of Part 2 of the Phase I/II study in adults aged 70 years and older. Top line immunogenicity and safety results are expected in the second half of 2026.
Strategic Deal with Vaxart
Dynavax executed a strategic deal to access a Phase IIb COVID-19 oral vaccine candidate from Vaxart. The program has enrolled over 5,400 subjects in a Phase IIb safety and efficacy study.
Share Repurchase Program
Authorization of a new $100 million share repurchase plan, reflecting confidence in the company's long-term growth and commitment to enhancing shareholder value.
Financial Performance
GAAP net income of $27 million for the third quarter of 2025, compared to $18 million in the third quarter of 2024. Non-GAAP adjusted EBITDA improved to $36 million, up from $25 million last year.
DVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Oct 24, 2025 | $10.38 | $10.49 | +1.06% |
Aug 07, 2025 | $11.06 | $10.33 | -6.60% |
May 06, 2025 | $10.92 | $9.72 | -10.99% |
Feb 20, 2025 | $13.33 | $13.33 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Dynavax Technologies (DVAX) report earnings?
Dynavax Technologies (DVAX) is schdueled to report earning on Feb 19, 2026, After Close (Confirmed).
What is Dynavax Technologies (DVAX) earnings time?
Dynavax Technologies (DVAX) earnings time is at Feb 19, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DVAX EPS forecast?
DVAX EPS forecast for the fiscal quarter 2025 (Q4) is 0.05.